SAN DIEGO, May 31, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Jefferies 2017 Healthcare Conference at 4:00 pm EDT on Wednesday, June 7, 2017, in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected]


Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 



